US 12,486,513 B2
Modulation of carbon flux through the meg and C3 pathways for the improved production of monoethylene glycol and C3 compounds
Ane Fernanda Beraldi Zeidler, Campinas (BR); Beatriz Leite Magalhaes, Campinas (BR); Lucas Pedersen Parizzi, Campinas (BR); and Veronica Maria Rodege Gogola Kolling, Campinas (BR)
Assigned to Braskem S.A., Sao Paulo (BR)
Filed by Braskem S.A., Sao Paulo (BR)
Filed on Dec. 27, 2019, as Appl. No. 16/728,509.
Claims priority of provisional application 62/786,294, filed on Dec. 28, 2018.
Claims priority of provisional application 62/786,298, filed on Dec. 28, 2018.
Claims priority of provisional application 62/786,282, filed on Dec. 28, 2018.
Claims priority of provisional application 62/786,283, filed on Dec. 28, 2018.
Claims priority of provisional application 62/786,304, filed on Dec. 28, 2018.
Prior Publication US 2020/0208160 A1, Jul. 2, 2020
Int. Cl. C12N 15/00 (2006.01); C12N 15/52 (2006.01); C12P 7/28 (2006.01)
CPC C12N 15/52 (2013.01) [C12P 7/28 (2013.01); C12Y 401/01047 (2013.01); C12Y 402/03003 (2013.01)] 15 Claims
 
1. A recombinant Escherichia coli capable of coproducing MEG and one or more C3 compounds, wherein the recombinant E. coli comprises:
a disruption of endogenous E. coli pta and one or more of the following (i) to (iii):
(i) a disruption of endogenous E. coli ackA,
(ii) a disruption of endogenous E. coli arcA, and
(iii) a disruption of endogenous E. coli pka;
wherein the recombinant E. coli comprises a pathway for MEG production; and
wherein one of the one or more C3 compounds is acetone and the recombinant E. coli comprises a pathway for acetone production.